Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
127540771 | 12754077 | 1 | I | 20100423 | 20100514 | 20160916 | 20160916 | EXP | US-ROCHE-703724 | ROCHE | 52.00 | YR | M | Y | 89.60000 | KG | 20160916 | MD | US | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
127540771 | 12754077 | 1 | PS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | 10MG/KG OVER 30-90 MINUTES ON DAYS 1 AND 15,LAST DOSE-26 MAR 2010-CYCLE 2, DAY 15, DOSE HELD | Y | U | 125085 | 950 | MG/KG | SOLUTION FOR INFUSION | |||||
127540771 | 12754077 | 2 | SS | Bevacizumab | BEVACIZUMAB | 1 | Intravenous (not otherwise specified) | Y | U | 125085 | 1900 | MG/KG | |||||||
127540771 | 12754077 | 3 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | CYCLE: 28 DAYS. FREQUENCY: ON DAYS 1, 8, 15 AND 22. LAST DOSE:16APR2010 CYCLE 3, DAY 8,DOSE HELD | Y | U | 0 | 75 | MG | ||||||
127540771 | 12754077 | 4 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | RESTARTED | Y | U | 0 | ||||||||
127540771 | 12754077 | 5 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | Y | U | 0 | 75 | MG | |||||||
127540771 | 12754077 | 6 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | Y | U | 0 | 50 | MG | |||||||
127540771 | 12754077 | 7 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | Y | U | 0 | 100 | MG | |||||||
127540771 | 12754077 | 8 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | Y | U | 0 | 100 | MG | |||||||
127540771 | 12754077 | 9 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | Y | U | 0 | 75 | MG | |||||||
127540771 | 12754077 | 10 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | Y | U | 0 | 100 | MG | |||||||
127540771 | 12754077 | 11 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | Y | U | 0 | 100 | MG | |||||||
127540771 | 12754077 | 12 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | Y | U | 0 | 100 | MG | |||||||
127540771 | 12754077 | 13 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | Y | U | 0 | 100 | MG | |||||||
127540771 | 12754077 | 14 | SS | TEMSIROLIMUS | TEMSIROLIMUS | 1 | Intravenous (not otherwise specified) | Y | U | 0 | 75 | MG |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
127540771 | 12754077 | 1 | Carcinoid tumour |
127540771 | 12754077 | 3 | Carcinoid tumour |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
127540771 | 12754077 | OT |
127540771 | 12754077 | HO |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
127540771 | 12754077 | Anal ulcer | |
127540771 | 12754077 | Hyperglycaemia | |
127540771 | 12754077 | Hyperkalaemia | |
127540771 | 12754077 | Hypertension | |
127540771 | 12754077 | Hypokalaemia | |
127540771 | 12754077 | Lower gastrointestinal haemorrhage | |
127540771 | 12754077 | Proctalgia | |
127540771 | 12754077 | Pulmonary haemorrhage | |
127540771 | 12754077 | Rectal haemorrhage |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
127540771 | 12754077 | 2 | 20100312 | 20100409 | 0 |